Formosa Pharmaceuticals Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Erick Co

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.8yrs
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Erick Co

1.8yrs

Mandato

Dr. Erick Co, Ph D., serves as Director of New Drug Development at ScinoPharm Taiwan, Ltd. Dr. Co serves as the Chief Executive Officer of Formosa Pharmaceuticals, Inc. and has been its President since 202...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Erick Co	President & CEO	1.8yrs	Nessun dato	Nessun dato
Nai Hsien Tsao	Director of Finance & CFO	less than a year	Nessun dato	Nessun dato
Helen Liu	Manager of Legal & Corporate Communications	less than a year	Nessun dato	Nessun dato
Ching Cheng Wei	Chief Business & Strategy Officer	less than a year	Nessun dato	Nessun dato

0.8yrs

Durata media

Gestione esperta: Il team dirigenziale di 6838 non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Formosa Pharmaceuticals Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Formosa Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: NT$0.37 loss per share (vs NT$1.07 loss in 3Q 2023)

Formosa Pharmaceuticals, Inc. Announces Successful Top-Line Results from CPN-303, a Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain After Cataract Surgery

New major risk - Share price stability

Formosa Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 11, 2024

New minor risk - Shareholder dilution

New minor risk - Share price stability

Eyenovia, Inc. Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S

Second quarter 2024 earnings released: NT$0.72 loss per share (vs NT$0.57 loss in 2Q 2023)

Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery

Full year 2023 earnings released: NT$2.59 loss per share (vs NT$3.82 loss in FY 2022)

Formosa Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

Third quarter 2023 earnings released: NT$1.08 loss per share (vs NT$0.89 loss in 3Q 2022)

Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery

Full year 2022 earnings released: NT$3.82 loss per share (vs NT$4.33 loss in FY 2021)

Less than half of directors are independent

Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery

Less than half of directors are independent

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media